References and Notes
<A NAME="RG03506ST-1A">1a</A>
Hoornaert G.
Bull. Soc. Chim. Belg.
1994,
103:
583
<A NAME="RG03506ST-1B">1b</A>
Kaval N.
Van der Eycken J.
Caroen J.
Dehaen W.
Strohmeier GA.
Kappe CO.
Van der Eycken E.
J. Comb. Chem.
2003,
5:
560
<A NAME="RG03506ST-1C">1c</A>
Kaval N.
Dehaen W.
Van der Eycken E.
J. Comb. Chem.
2005,
7:
90 ; and references cited therein
<A NAME="RG03506ST-1D">1d</A>
Jiang B.
Yang C.-G.
Wang J.
J. Org. Chem.
2001,
66:
4865
<A NAME="RG03506ST-1E">1e</A>
Heeres J.
de Jonge MR.
Koymans LMH.
Daeyaert FFD.
Vinkers M.
Van Aken KJA.
Arnold E.
Das K.
Kilonda A.
Hoornaert GJ.
Compernolle F.
Cegla M.
Azzam RA.
Andries K.
de Bethune M.-P.
Azijn H.
Pauwels R.
Lewi PJ.
Janssen PAJ.
J. Med. Chem.
2005,
48:
1910
<A NAME="RG03506ST-1F">1f</A>
Parlow JJ.
Case BL.
Dice TA.
Fenton RL.
Hayes MJ.
Jones DE.
Neumann WL.
Wood RS.
Lachance RM.
Girard TJ.
Nicholson NS.
Clare M.
Stegeman RA.
Stevens AM.
Stallings WC.
Kurumbail RG.
South MS.
J. Med. Chem.
2003,
46:
4050
<A NAME="RG03506ST-2A">2a</A>
Kaval N.
Ermolat’ev D.
Appukkuttan P.
Dehaen W.
Kappe CO.
Van der Eycken E.
J. Comb. Chem.
2005,
7:
490
<A NAME="RG03506ST-2B">2b</A>
Kaval N.
Dehaen W.
Kappe CO.
Van der Eycken E.
Org. Biomol. Chem.
2004,
2:
154
<A NAME="RG03506ST-2C">2c</A>
Van der Eycken E.
Appukkuttan P.
De Borggraeve W.
Deahen W.
Dallinger D.
Kappe CO.
J. Org. Chem.
2002,
67:
7904
<A NAME="RG03506ST-3">3</A>
De Borggraeve WM.
Rombouts FJR.
Van der Eycken EV.
Toppet SM.
Hoornaert GJ.
Tetrahedron Lett.
2001,
42:
5693
<A NAME="RG03506ST-4">4</A>
Pawar VG.
De Borggraeve WM.
Maes V.
Tourwe DA.
Compernolle F.
Hoornaert GJ.
Tetrahedron Lett.
2005,
46:
1707
<A NAME="RG03506ST-5">5</A>
De Borggraeve WM.
Verbist BMP.
Rombouts FJR.
Pawar VG.
Smets WJ.
Kamoune L.
Alen J.
Van der Eycken EV.
Compernolle F.
Hoornaert GJ.
Tetrahedron
2004,
60:
11597
<A NAME="RG03506ST-6A">6a</A>
Stille JK.
Angew. Chem.
1986,
98:
504
<A NAME="RG03506ST-6B">6b</A>
Stille JK.
Simpson JH.
J. Am. Chem. Soc.
1987,
109:
2138
<A NAME="RG03506ST-6C">6c</A>
Farina V.
Pure Appl. Chem.
1996,
68:
73
<A NAME="RG03506ST-6D">6d</A>
Bedford RB.
Hazelwood SL.
Limmert ME.
Albisson DA.
Draper SM.
Scully PN.
Coles SJ.
Hursthouse MB.
Chem. Eur. J.
2003,
9:
3216 ; and references cited therein
<A NAME="RG03506ST-7">7</A>
Kaval N.
Bisztray K.
Dehaen W.
Kappe CO.
Van der Eycken E.
Mol. Diversity
2003,
7:
125
<A NAME="RG03506ST-8A">8a</A>
Iyoda M.
Miura M.
Sasaki S.
Kabir SMH.
Kuwatani Y.
Yoshida M.
Tetrahedron Lett.
1997,
38:
4581
<A NAME="RG03506ST-8B">8b</A>
Corsico BM.
Rossi RA.
Synlett
2000,
230
<A NAME="RG03506ST-8C">8c</A>
Broutin P.-E.
Čerňa I.
Companiello M.
Leroux F.
Colbert F.
Org. Lett.
2004,
6:
4419
<A NAME="RG03506ST-8D">8d</A>
Cahiez G.
Chaboche C.
Mahuteau-Betzer F.
Ahr M.
Org. Lett.
2005,
7:
1943
<A NAME="RG03506ST-8E">8e</A>
Micozzia A.
Ottaviania M.
Giardinaa G.
Riccia A.
Pizzoferratob R.
Zillerb T.
Compagnone D.
Lo Sterzoc C.
Adv. Synth. Catal.
2005,
347:
143
<A NAME="RG03506ST-9">9</A>
Arvela RK.
Leadbeater NE.
Org. Lett.
2005,
7:
2101
<A NAME="RG03506ST-10A">10a</A>
Chen JJ.
Deshpande SV.
Tetrahedron Lett.
2003,
44:
8873
<A NAME="RG03506ST-10B">10b</A>
Humphrey CE.
Easson MAM.
Tierney JP.
Turner NJ.
Org. Lett.
2003,
5:
849
<A NAME="RG03506ST-10C">10c</A>
Katritzky AR.
Zhang Y.
Singh SK.
Steel PJ.
Arkivoc
2003,
(xv):
47
<A NAME="RG03506ST-11">11</A>
Representative Experimental Procedure Using a Dedicated Multimode Microwave Apparatus
- Synthesis of 1,3-Dibenzyl-5-chloro-6-methylpyrazin-2 (1
H
)-one (
3e).
Pyrazinone 1e (0.324 g, 1.0 mmol), bromide 2a (0.205 g, 1.2 mmol, 1.2 equiv), hexabutyldistannane (0.649 g, 1.1 mmol, 1.1 equiv)
and Pd(Ph3P)4 (0.058 g, 5 mol%) were suspended in DMF (12 mL) in a 50 mL glass vial equipped with
a small magnetic stirring bar. The mixture was irradiated in the cavity of a Milestone-MYCROSYNTH
multimode oven at a preselected maximum temperature of 170 °C for 10 min, using a
maximum irradiation power of 120 W. The mixture was then cooled to r.t., poured into
crushed ice, diluted with Et2O and the contents were stirred at r.t. for 2 h. It was then extracted with Et2O and dried over MgSO4. The solvent was removed under reduced pressure and the crude residue was subjected
to column chromatography (silica gel, PE-EtOAc, 3:1) as eluent to afford analytically
pure product 3e (0.224 g, 69%) as a viscous oil. 1H NMR (300 MHz, CDCl3): δ = 7.17-7.35 (m, 10 H), 5.38 (s, 2 H), 4.12 (s, 2 H), 2.49 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 158.2, 153.3, 136.1, 134.1, 133.9, 129.2, 129.0, 128.5, 127.2, 127.0, 126.4,
123.2, 50.2, 39.1, 16.9 ppm. MS (CI): m/z (%) = 325 (100) [MH+]. HRMS (EI): m/z calcd for C19H17N2ClO: 324.1029; found: 324.1034.
<A NAME="RG03506ST-12">12</A>
3-Benzyl-5-chloro-1-(4-methoxybenzyl)-2(1
H
)-pyrazinone (
3a).
Mp 102-103 °C. 1H NMR (300 MHz, CDCl3): δ = 3.8 (s, 3 H), 4.12 (s, 2 H), 4.93 (s, 2 H), 6.9 (d, 2 H, J = 8.7 Hz), 7.01 (s, 1 H), 7.30-7.35 (m, 5 H), 7.44 (d, 2 H, J = 7.0 Hz) ppm. 13C NMR (75 MHz, CDCl3): δ = 39.8, 51.8, 55.2, 114.4, 124.3, 125.7, 125.8, 126.5, 128.3, 129.3, 130.2, 136.3,
154.4, 158.8, 159.8 ppm. MS (CI): m/z (%) = 341 [MH+], 121 (100). HRMS (EI): m/z calcd for C19H17N2ClO2: 340.0978; found: 340.0972.
3-Benzyl-5-chloro-(3-phenylpropyl)-2(1
H
)-pyrazinone (
3b).
Mp 98-100 °C. 1H NMR (300 MHz, CDCl3): δ = 2.03-2.19 (m, 2 H), 2.68 (t, J = 7.35 Hz, 2 H), 3.84 (t, J = 7.35 Hz, 2 H), 4.12 (s, 2 H), 6.92 (s, 1 H, C-6H), 7.15-7.44 (m, 10 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 29.6, 32.7, 39.9, 49.8, 125.3, 125.6, 126.3, 126.7, 128.2, 128.3, 128.4, 128.6,
136.0, 139.0, 154.5, 158.9 ppm. MS (CI): m/z (%) = 339 (100) [MH+]. HRMS (EI): m/z calcd for C20H19N2ClO: 338.1185; found: 338.1194.
3-Benzyl-5-chloro-1-cyclohexylmethyl-2(1
H
)-pyrazinone (
3c).
Mp 107-108 °C. 1H NMR (300 MHz, CDCl3): δ = 1.13-1.90 (m, 11 H), 3.78 (d, J = 7.41 Hz, 2 H), 4.10 (s, 2 H), 7.21 (s, 1 H), 7.12-7.18 (m, 3 H), 7.32 (d, J = 7.32 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 25.5, 26.1, 30.6, 36.8, 40.2, 57.4, 122.4, 126.2, 126.7, 128.4, 129.3, 136.5,
154.1, 158.7 ppm. MS (CI): m/z (%) = 317 (100) [MH+]. HRMS (EI): m/z calcd for C18H21N2ClO: 316.1342; found: 316.1344.
3-Benzyl-5-chloro-1-cyclohexyl-2(1
H
)-pyrazinone (
3d).
Mp 139-140 °C. 1H NMR (300 MHz, CDCl3): δ = 1.37-1.91 (m, 10 H), 4.10 (s, 2 H), 4.68-4.76 (m, 1 H), 7.12 (s, 1 H), 7.18-7.30
(m, 3 H), 7.41 (d, J = 7.32 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 25.2, 25.6, 30.0, 40.3, 55.5, 121.8, 126.2, 126.7, 128.5, 129.6, 136.7, 154.2,
158.6 ppm. MS (CI): m/z 303 (100) [MH+]. HRMS (EI): m/z calcd for C17H19N2ClO: 302.1185; found: 302.1184.
3-Benzyl-5-chloro-1,6-diphenyl-2(1
H
)-pyrazinone (
3f).
Mp 180-181 °C. 1H NMR (300 MHz, CDCl3): δ = 4.12 (s, 2 H), 6.96-7.84 (m, 15 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 40.2, 125.6, 126.87, 128.2, 128.2, 28.6, 128.7, 129.0, 129.1, 129.8, 130.0,
130.7, 131.2, 136.7, 137.2, 155.5, 158.3 ppm. MS (CI): m/z (%) = 373 (100) [MH+]. HRMS (EI): m/z calcd for C23H17N2ClO: 372.1029; found: 372.1020.
5-Chloro-3-(4-methoxybenzyl)-1,6-diphenyl-2(1
H
)-pyrazinone (
3g).
Mp 194-195° °C. 1H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3 H), 4.16 (s, 2 H,), 6.89 (d, 2 H, J = 8.47 Hz), 6.96-7.29 (m, 10 H), 7.49 (d, 2 H, J = 8.29 Hz) ppm. 13C NMR (75 MHz, CDCl3): δ = 39.8, 55.3, 114.0, 125.6, 128.2, 128.7, 129.0, 129.2, 130.0, 130.8, 131.3,
136.4, 137.2, 155.1, 158.3, 159.5 ppm. MS (CI): m/z (%) = 403 (100) [MH+]. HRMS (EI): m/z calcd for C24H19N2ClO2: 402.1135; found: 402.1142.
5-Chloro-3-(4-methoxybenzyl)-1-(3-phenylpropyl)-2(1
H
)-pyrazinone (
3h).
Mp 113-114 °C. 1H NMR (300 MHz, CDCl3): δ = 2.03-2.08 (m, 2 H), 2.66 (t, J = 7.32 Hz, 2 H), 3.75 (s, 3 H), 3.82 (t, J = 7.32 Hz, 2 H), 4.03 (s, 2 H), 6.83 (d, J = 8.22 Hz, 2 H), 6.99 (s, 1 H), 7.14 (d, J = 6.39 Hz, 2 H), 7.19-7.28 (m, 5 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 29.7, 32.7, 39.1, 49.8, 55.2, 113.9, 125.2, 125.7, 126.7, 128.2, 128.5, 128.6,
130.5, 140.0, 154.6, 158.5, 159.2 ppm. MS (CI): m/z = 369 (100) [MH+]. HRMS (EI): m/z calcd for C21H21N2ClO2: 368.1291; found: 368.1287.
5-Chloro-1-(3-phenylpropyl)-3-(3,4,5-trimethoxy-benzyl)-2(1
H
)-pyrazinone (
3i).
Mp 104-105 °C. 1H NMR (300 MHz, CDCl3): δ = 2.05-2.10 (m, 2 H), 2.67 (t, J = 7.44 Hz, 2 H), 3.80-3.88 (m, 11 H), 4.03 (s, 2 H), 6.67 (s, 2 H), 7.02 (s, 1 H),
7.15-7.30 (m, 5 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 29.8, 32.8, 40.1, 50.0, 56.2, 56.3, 55.4, 106.5, 125.5, 125.7, 126.5, 128.3,
128.7, 132.3, 136.8, 140.0, 153.2, 153.3, 154.7, 158.7 ppm. MS (CI): m/z (%) = 429 (100) [MH+]. HRMS (EI): m/z calcd for C23H25N2ClO4: 428.1502; found: 428.1499.
5-Chloro-3-(2-fluorobenzyl)-1-(3-phenylpropyl)-2(1
H
)-pyrazinone (
3j).
Mp 97-98 °C. 1H NMR (300 MHz, CDCl3): δ = 2.03-2.13 (m, 2 H), 2.67 (t, J = 7.40 Hz, 2 H), 3.85 (t, J = 7.47 Hz, 2 H), 4.15 (s, 2 H), 7.01 (s, 1 H), 7.02-7.31 (m, 9 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 29.8, 32.8, 33.2, 49.9, 115.6, 124.0, 125.5, 125.8, 126.5, 128.3, 128.5, 128.7,
131.5, 131.6, 140.1, 154.5, 158.7, 162.9 ppm. MS (CI): m/z (%) = 357 (100) [MH+]. HRMS (EI): m/z calcd for C20H18N2FClO: 356.1092; found: 356.1098.
3-Allyl-5-chloro-1-(3-phenylpropyl)-2(1
H
)-pyrazinone (
3m).
Viscous oil. 1H NMR (300 MHz, CDCl3): δ = 2.05-2.13 (m, 2 H), 2.22 (dd, J = 1.83, 5.49 Hz, 2 H), 2.71 (t, J = 7.34 Hz, 2 H), 3.89 (t, J = 7.30 Hz, 2 H), 6.83 (dd, J = 1.88, 14.16 Hz, 2 H), 6.99 (s, 1 H), 7.17-7.33 (m, 6 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 30.1, 31.9, 33.1, 50.2, 124.6, 124.5, 125.8, 126.8, 128.6, 129.1, 139.3, 140.5,
152.3, 154.7 ppm. MS (CI): m/z (%) = 289 (100) [MH+]. HRMS (EI): m/z calcd for C16H17N2ClO: 288.1029; found: 288.1034. Anal. Calcd for C16H17N2ClO: C, 66.55; H, 5.93; N, 9.70. Found: C, 66.60; H, 5.97; N, 9.68.